ReviewBasic research in cardiology2013
How can we cure a heart "in flame"? A translational view on inflammation in heart failure.
Review in Basic research in cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 107 citations in OpenAlex.
- Qiliqiangxin Alleviates Imbalance of Inflammatory Cytokines in Patients with Dilated Cardiomyopathy: A Randomized Controlled Trial.Current medical science · 2024Trial
- Complement C3c as a biomarker in heart failure.Mediators of inflammation · 2013Trial
- Inadequate Preventive Dental Care Is Associated With Higher Cardiovascular Risk Identified by ECG-Based Artificial Intelligence Algorithms.Journal of the American Heart Association · 2026Article
- Establishment and Validation of Nomogram Model Based on Neutrophil Lymphocyte Ratio for Prognosis of Patients With Congestive Heart Failure.Cardiology research and practice · 2026Article
- Systemic Inflammatory Biomarkers (Interleukin-6, High-Sensitivity C-Reactive Protein, and Neutrophil-to-Lymphocyte Ratio) and Prognosis in Heart Failure: A Meta-Analysis of Prospective Cohort Studies.Journal of clinical medicine · 2025Review
- Machine Learning Reveals Novel Pediatric Heart Failure Phenotypes with Distinct Mortality and Hospitalization Outcomes.Diagnostics (Basel, Switzerland) · 2025Article
- Unveiling the Systemic Impact of Congestion in Heart Failure: A Narrative Review of Multisystem Pathophysiology and Clinical Implications.Journal of cardiovascular development and disease · 2025Review
- The Role of Cardiac Troponin and Other Emerging Biomarkers Among Athletes and Beyond: Underlying Mechanisms, Differential Diagnosis, and Guide for Interpretation.Biomolecules · 2024Review
- Interface Between Cardioimmunology, Myocardial Health, and Disease: A Compendium.Circulation research · 2024Article
- Targeting Key Inflammatory Mechanisms Underlying Heart Failure: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Temporal expression and spatial distribution of the proteoglycan versican during cardiac fibrosis development.Matrix biology plus · 2023Article
- Circulating immune checkpoints predict heart failure outcomes.ESC heart failure · 2023Article
- Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation.Circulation research · 2023Article
- The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review.Current oncology (Toronto, Ont.) · 2022Article
- Inhibition of thioredoxin-interacting protein may enhance the therapeutic effect of dehydrocostus lactone in cardiomyocytes under doxorubicin stimulation via the inhibition of the inflammatory response.Experimental and therapeutic medicine · 2022Article
- Leukocyte count and the risk of adverse outcomes in patients with HFpEF.BMC cardiovascular disorders · 2021Article
- Recent updates on novel therapeutic targets of cardiovascular diseases.Molecular and cellular biochemistry · 2021Review
- Multimodality Imaging of Inflammation and Ventricular Remodeling in Pressure-Overload Heart Failure.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.Circulation research · 2019Review
- T-cell recruitment to the heart: friendly guests or unwelcome visitors?American journal of physiology. Heart and circulatory physiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of chronic heart failure is still increasing making it a major health issue in the 21st century. Tremendous evidence has emerged over the past decades that heart failure is associated with a wide array of mechanisms subsumed under the term "inflammation". Based on the great success of immuno-suppressive treatments in auto-immunity and transplantation, clinical trials were launched targeting inflammatory mediators in patients with chronic heart failure. However, they widely lacked positive outcomes. The failure of the initial study program directed against tumor necrosis factor-α led to the search for alternative therapeutic targets involving a broader spectrum of mechanisms besides cytokines. We here provide an overview of the current knowledge on immune activation in chronic heart failure of different etiologies, summarize clinical studies in the field, address unresolved key questions, and highlight some promising novel therapeutic targets for clinical trials from a translational basic science and clinical perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.